Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Clinical Insight on Semaglutide for Chronic Weight Management in Adults: Patient Selection and Special Considerations
Ariana M. Chao, Jena Shaw Tronieri, Anastassia Amaro, et al.
Drug Design Development and Therapy (2022) Vol. Volume 16, pp. 4449-4461
Open Access | Times Cited: 36

Showing 1-25 of 36 citing articles:

Advantages and Limitations of the Body Mass Index (BMI) to Assess Adult Obesity
Yilun Wu, Dan Li, Sten H. Vermund
International Journal of Environmental Research and Public Health (2024) Vol. 21, Iss. 6, pp. 757-757
Open Access | Times Cited: 43
Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review
Cătălin Vlăduț Ionuț Feier, Razvan Constantin Vonica, Alaviana Monique Faur, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 8, pp. 4346-4346
Open Access | Times Cited: 13
Molecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesity
Rafael Tamayo‐Trujillo, Viviana A. Ruiz‐Pozo, Santiago Cadena-Ullauri, et al.
Frontiers in Nutrition (2024) Vol. 11
Open Access | Times Cited: 12
Emerging Pharmacotherapies for Obesity: A Systematic Review
Michail Kokkorakis, Marlene Chakhtoura, Caline Rhayem, et al.
Pharmacological Reviews (2024) Vol. 77, Iss. 1, pp. 100002-100002
Open Access | Times Cited: 7
GLP-1RA Essentials in Gastroenterology: Side Effect Management, Precautions for Endoscopy and Applications for Gastrointestinal Disease Treatment
Justin W. L. Wan, Caesar Ferrari, Micheal Tadros
Gastroenterology Insights (2024) Vol. 15, Iss. 1, pp. 191-212
Open Access | Times Cited: 6
Emerging role of GLP-1 agonists in cardio-metabolic therapy - Focus on Semaglutide
Celestine I. Odigwe, Rajasekhar Mulyala, H. A. Malik, et al.
American Heart Journal Plus Cardiology Research and Practice (2025) Vol. 52, pp. 100518-100518
Open Access
Achieving Over 30% Body Weight Loss With Semaglutide in a Patient: A Case Report
Sidra Danish, Vallabh Dogra, Uzma Rauf, et al.
Cureus (2025)
Open Access
Pregnancy Outcomes After Semaglutide Exposure
Line Kolding, Jakob Nørgaard Henriksen, Eva Aggerholm Sædder, et al.
Basic & Clinical Pharmacology & Toxicology (2025) Vol. 136, Iss. 4
Open Access
Giving weight to incretin-based pharmacotherapy for obesity-related sleep apnea: a revolution or a pipe dream?
Ronald R. Grunstein, Thomas A. Wadden, Julia L. Chapman, et al.
SLEEP (2023) Vol. 46, Iss. 10
Open Access | Times Cited: 11
Semaglutide, Testosterone and Sildenafil advertising on social media: The Normalisation of lifestyle enhancement drugs
Mikey Hirst, Luke A. Turnock
Performance Enhancement & Health (2024), pp. 100303-100303
Open Access | Times Cited: 3
A phase 1, randomized, double‐blind, placebo‐controlled trial investigating the pharmacokinetics, pharmacodynamics, safety and tolerability of oral semaglutide in healthy Chinese subjects
Panpan Xie, Morten T. Abildlund, Tine A. Bækdal, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 8, pp. 3068-3077
Open Access | Times Cited: 3
Semaglutide in the spotlight: weighing benefits against rising concerns
Patrick Ashinze, Toufik Abdul‐Rahman, Wireko Andrew Awuah
Therapeutic Advances in Endocrinology and Metabolism (2024) Vol. 15
Open Access | Times Cited: 2
Semaglutide-induced Hyperemesis Gravidarum
Ijeoma Gloria Okeke, Amanda Rose Camarda, Richard Okeke, et al.
JCEM Case Reports (2024) Vol. 2, Iss. 2
Open Access | Times Cited: 2
Charting New Territories in Obesity Management- Traditional Techniques to Tirzepatide
Areeba Fareed, Laura Ghanem, Rayyan Vaid, et al.
Endocrine Practice (2024)
Closed Access | Times Cited: 2
Treatment sequencing using the dual amylin and calcitonin receptor agonist KBP-336 and semaglutide results in durable weight loss
Anna Thorsø Larsen, M.A. Karsdal, Kim Henriksen
European Journal of Pharmacology (2023) Vol. 954, pp. 175837-175837
Closed Access | Times Cited: 6
What do adults living with obesity want from a chatbot for physical activity? – a qualitative study
Dillys Larbi, Rolf Wynn, Marianne V. Trondsen, et al.
BMC Digital Health (2024) Vol. 2, Iss. 1
Open Access | Times Cited: 1
Effect of Semaglutide in Individuals With Obesity or Overweight Without Diabetes
Mokhlef Alanazi, Jaber Abdullah Alshahrani, Ahmed Sulayman Aljaberi, et al.
Cureus (2024)
Open Access | Times Cited: 1
Semaglutide use in people with obesity and type 2 diabetes from real‐world utilization data: An analysis of the All of US Program
Craig S. Mayer, Paul Fontelo
Diabetes Obesity and Metabolism (2024)
Open Access | Times Cited: 1
The Neurobiology of Eating Behavior in Obesity: Mechanisms and Therapeutic Targets: A Report from the 23rd Annual Harvard Nutrition Obesity Symposium
Imen Becetti, Esther L Bwenyi, Ivan E. de Araújo, et al.
American Journal of Clinical Nutrition (2023) Vol. 118, Iss. 1, pp. 314-328
Open Access | Times Cited: 3
Clinician resistance to broaching the topic of weight in primary care: Digging deeper into weight management using strong structuration theory
Anisa Hajizadeh, Laura Heath, Aryati Ahmad, et al.
Social Science & Medicine (2023) Vol. 329, pp. 115997-115997
Open Access | Times Cited: 3
A Semaglutida aplicada ao tratamento da obesidade: perspectivas clínicas na literatura
Maria Carolina Alves Zanatta, Fabiana Sambini da Rocha, Tarcísia Alves Sambini Fumagali, et al.
Research Society and Development (2023) Vol. 12, Iss. 9, pp. e10012943295-e10012943295
Open Access | Times Cited: 3
SPAG7 deletion causes intrauterine growth restriction, resulting in adulthood obesity and metabolic dysfunction
Stephen E Flaherty, Olivier Bézy, Brianna LaCarubba Paulhus, et al.
(2024)
Open Access
Cardiovascular Implications of Semaglutide in Obesity Management: Redefining Cardiovascular Health Strategies
Aditya John Binu, Nitin Kapoor
Heart International (2024) Vol. 18, Iss. 1
Open Access
SPAG7 deletion causes intrauterine growth restriction, resulting in adulthood obesity and metabolic dysfunction
Stephen E Flaherty, Olivier Bézy, Brianna LaCarubba Paulhus, et al.
eLife (2024) Vol. 12
Open Access
GLP-1 analogue semaglutide regulates pancreatic beta-cell proliferation via PDX-1 expression control
Ming Liang, JiaHui Sun, X. Chu, et al.
Theoretical and Natural Science (2024) Vol. 46, Iss. 1, pp. 46-54
Open Access
Page 1 - Next Page

Scroll to top